Breast Cancer

Bayer and Onyx have launched a number of clinical trials in breast cancer. For a more comprehensive list of Nexavar® (sorafenib) clinical trials, please visit clinicaltrials.gov or call 866-738-3021.

Phase 3 Study of Nexavar in Combination with Capecitabine - RESILIENCE
Currently Enrolling
Study Design: Randomized, double-blind, placebo-controlled trial
Patients:
Locally advanced or metastatic HER2 negative breast cancer patients who have failed prior taxane and an anthracycline containing chemotherapy regimen or for whom further anthraycycline therapy is not indicated and have failed no more than one prior chemo for locally advanced or metastatic disease
Purpose: To determine the effectiveness of Nexavar in combination with capecitabine vs. capecitabine alone by assessing the difference in progression-free survival (PFS). In addition, the study will evaluate other measures of efficacy and safety
Location:
Multiple centers throughout the United States, Europe, Russia, Latin America, and the Asia-Pacific region

Phase 2 Study of Nexavar plus Gemcitabine or Capecitabine in Avastin Progressors
Enrollment Complete
Study Design: Randomized, double-blind, placebo-controlled trial
Patients: Locally recurrent or metastatic HER2 negative breast cancer patients whose progressive disease has occurred during or after treatment with Avastin
Purpose: To determine the effectiveness of Nexavar plus gemcitabine or capecitabine vs. placebo plus gemcitabine or capecitabine by assessing the difference in progression-free survival (PFS). In addition, the study will evaluate other measures of efficacy and safety
Location: Multiple centers throughout the United States

Phase 2 Study of Nexavar in Combination with Docetaxel and/or Letrozole Currently Enrolling
Study Design: Randomized, double-blind, placebo-controlled trial
Patients: Locally recurrent or metastatic HER2-neu negative breast cancer patients who have not previously received systemic therapy
Purpose: To determine the effectiveness of Nexavar plus docetaxel, Nexavar plus letrozole, or Nexavar plus docetaxel and letrozole, when compared to docetaxel and/or letrozole treatments alone by assessing the difference in progression-free survival (PFS). In addition, the study will evaluate other measures of efficacy and safety
Location: Italy, Germany, Russia, Poland

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204